Survodutide Raw Material Powder 99%min Clinical grade

Product Description – Survodutide API (BI-456906)

Overview
Survodutide (also known as BI-456906) is an investigational peptide designed as a dual agonist of the GLP-1 and glucagon receptors, developed for weekly subcutaneous administration to support weight reduction by simultaneously increasing energy expenditure and suppressing appetite Zealand Pharma.

Key Features

• Structure & Modification:

  • A 29-amino-acid synthetic peptide

  • Contains a C18 fatty acid acylation to extend half-life via albumin binding, enabling once-weekly dosing.

• Mechanism of Action:

  • Potent dual activity: GLP-1 and glucagon receptor agonism enhances satiety and energy use, resulting in robust weight loss.

API Grade Details

• Produced under GMP-certified conditions, ensuring consistent high quality suitable for research or further development.

• Available with full documentation including Certificate of Analysis (CoA), suitable for regulatory purposes. Suppliers may offer material conforming to pharmacopeial standards (e.g., USP, EP, JP); please specify desired purity, salt form (HCl, base), or other attributes when requesting quotes.

Product Stability

• Available formulations demonstrate strong shelf life, with stability of ≥ 4 years under proper storage conditions.

Casing in Brief